Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7090-7097

  Recalde, Sergio ^a   Zarranz Ventura, Javier ^a,b   Fernándezrobredo, Patricia ^a   García Gómez, Pío J ^b   Salinas Alamán, Angel ^b   Borrás Cuesta, Francisco ^c   Dotor, Javier ^d   García Layana, Alfredo ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Digna Biotech   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISITERTIDE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P17; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; P17 PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; TGF BETA1 TYPE III RECEPTOR (730 743), HUMAN; TGF-BETA1 TYPE III RECEPTOR (730-743), HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIODE LASER; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; LOW DRUG DOSE; MALE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; SUBRETINAL NEOVASCULARIZATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; LONG EVANS RAT; METABOLISM; PATHOLOGY;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN ANGIOGRAPHY; INJECTIONS, INTRAVENOUS; INTRAVITREAL INJECTIONS; LASER COAGULATION; LASERS, SEMICONDUCTOR; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, LONG-EVANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80155147046     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7300     Document Type: Article

References (42)

1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
2. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol. 2000;184:301-310.
3. Arnold JJ, Sarks SH. Extracts from "clinical evidence": age related macular degeneration. BMJ. 2000;321:741-744.
4. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003; 110:1297-1305.
5. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12:127-133.
6. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308: 385-389.
7. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol. 2006;51:316-363.
8. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA. 2007;104:16227-16232.
9. Recalde S, Fernandez-Robredo P, Altarriba M, Salinas-Alaman A, García-Layana A. Age-related macular degeneration genetics (abstract). Ophthalmology. 2008;115:916, 916 e1.
10. Christen WG, Glynn RJ, Manson JE, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-1151.
11. Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr Opin Ophthalmol. 2004;15: 197-202.
12. Fernandez-Robredo P, Maestre SR, Zarranz-Ventura J, Mulero HH, Salinas-Alaman A, Garcia-Layana A. Myopic choroidal neovascularization genetics (abstract). Ophthalmology. 2008;115:1632, e1632.
13. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol. 2003;87: 570-573.
14. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol. 1998;116:506-513.
15. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and agerelated macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-374.
16. Bhutto LA, McLeods DS, Hasegawa T, et al. Pigment epitheliumderived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82:99-110.
17. Lu M, Adamis AP. Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am. 2006;19:323-334.
18. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004;242:91-101.
19. Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, Honda Y. Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina. 2005;25:911-918.
20. Nagineni CN, Samuel W, Nagineni S, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197:453-462.
21. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35:3178-3188.
22. Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, Uyama M. Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr Eye Res. 1997; 16:9-18.
23. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007;84:812-822.
24. Gil-Guerrero L, Dotor J, Huibregtse IL, et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1. J Immunol. 2008;181:126-135.
25. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol. 2005;125: 450-455.
26. Ezquerro IJ, Lasarte JJ, Dotor J, et al. A synthetic peptide from transforming growth factor b type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine. 2003;21:1-9.
27. Dotor J, López-Vázquez AB, Lasarte JJ, et al. Identification of peptide inhibitors of transforming growth factor β 1 using a phagedisplayed peptide library. Cytokine. 2007;39:106-115.
28. Serrati S, Margheri F, Pucci M, et al. TGFβ1 antagonistic peptides inhibit TGFβ1-dependent angiogenesis. Biochem Pharmacol. 2009;77:813-825.
29. Vicent S, Luis-Ravelo D, Antón I, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res. 2008;68:2275-2285.
30. Hermida N, López B, González A, et al. A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res. 2009;81:601-609.
31. García-Layana A, Vásquez G, Salinas-Alamán A, Moreno-Montañés J, Recalde S, Fernández-Robredo P. Development of laser-induced choroidal neovascularization in rats after retinal damage by sodium iodate injection. Ophthalmic Res. 2009;42:205-212.
32. Merrifield RB. Solid phase peptide synthesis, I: the synthesis of a tetrapeptide. J Am Chem Soc. 1963;85:2149-2154.
33. Atherton E, Logan JC, Sheppard RC. Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenyl methoxycarbonyl aminoacids on polyamide supports: synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J Chem Soc Perkin Trans. 1989;1:538-546.
34. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91:537-543.
35. Ip MS, Scott IU, Brown GC, et al. Antivascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837-1846.
36. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247:311-318.
37. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144:627-637.
38. Caballero S, Swaney J, Moreno K, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res. 2009;88:367-377.
39. Stahl A, Paschek L, Martin G, et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPEinduced sprouting angiogenesis in vitro. FEBS Lett. 2008;582: 3097-3102.
40. Kim JH, Kim JH, Yu YS, et al. Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor. Mol Vis. 2008;14:556-561.
41. Rohrer B, Long Q, Coughlin B, et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3056-3064.
42. Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol. 2007;44:3901-3908.